title: Agents for refractory/relapsed acute lymphocytic leukemia in adults.
abstract: Although treatment results for adult acute lymphoblastic leukemia (ALL) have improved considerably in the past decades, treating adult patients with relapsed/refractory acute lymphocytic leukemia (ALL) is still difficult. Adults with refractory/relapsed acute lymphocytic leukemia (ALL) processed to death rapidly associated with chemotherapy resistance, high mortality by reinduction, etc. Only 20% to 30% of those patients acquired complete remission (CR). Those patients are always of short duration unless an allogeneic stem cell transplant is feasible. Median survival is only ranging from 2 to 12 months. Therapeutic strategy on relapsed/refractory acute lymphocytic leukemia (ALL) is always a major therapeutic challenge bothering hematological researchers. Novel agents and unique therapeutic strategies have been developed in recent years. This review focuses on major clinical advances in the agents for refractory/relapsed ALL.
authors.affiliation: Department of Hematology, Navy General Hospital of PLA, Fucheng Road, Beijing, PR China. qlr2007@126.com.
authors.forename: L-R
authors.initials: LR
authors.lastname: Qian
authors.forename: W
authors.initials: W
authors.lastname: Fu
authors.forename: J-L
authors.initials: JL
authors.lastname: Shen
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D016879:Salvage Therapy; D055815:Young Adult